Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Not Confirmed
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Industry Trade Show
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Digital content

11 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-raises-45-million-in-series-b-financing-led-by-astrazeneca-cicc-302553734.html

05 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-yolt-101-an-in-vivo-base-editing-therapy-to-treat-heterozygous-familial-hypercholesterolemia-hefh-302475072.html

28 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-announces-first-clinical-data-from-ongoing-investigator-initiated-trial-of-yolt-101-an-in-vivo-base-editing-therapy-for-familial-hypercholesterolemia-302439382.html

25 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-positive-clinical-data-for-yolt-203-an-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1-ph1-302384408.html

22 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-to-initiate-a-clinical-trial-for-yolt-204-a-first-in-class-bone-marrow-targeted-in-vivo-gene-editing-therapy-for--thalassemia-302355739.html

21 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-successful-completion-of-dose-escalation-phase-in-phase-i-trial-of-yolt-201-for-attr-302337849.html
ABOUT THIS PAGE